Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Filings indexed 894 across all filing types
Latest filing 2024-11-05 Regulatory Filings
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2024-11-05 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-05 English
8-K
Regulatory Filings
2024-10-30 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-10-22 English
FORM 4
Director's Dealing
2024-10-09 English
FORM 4
Director's Dealing
2024-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.